804 results
Keyword Flecainide Teva Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Raloxifene Teva
raloxifene hydrochloride, Osteoporosis, Postmenopausal
Date of authorisation: 29/04/2010,
, Revision: 10, Authorised, Last updated: 27/09/2021
Raloxifene Teva Musculoskeletal Diseases Bone … Report (EPAR) for Raloxifene Teva. It explains how the Committee … conditions of use for Raloxifene Teva. What is Raloxifene Teva? Raloxifene Teva is a medicine that contains … -
List item
Human medicine European public assessment report (EPAR): Docetaxel Teva Pharma
docetaxel, Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Prostatic Neoplasms
Date of authorisation: 21/01/2011,, Revision: 6, Withdrawn, Last updated: 21/01/2014
Docetaxel Teva Pharma Carcinoma, Non-Small-Cell … Docetaxel Teva Pharma … ublic statement on Docetaxel Teva Pharma 7 Westferry … -
List item
Human medicine European public assessment report (EPAR): Lamivudine Teva Pharma B.V.
lamivudine, HIV Infections
Date of authorisation: 10/12/2009,, Revision: 19, Authorised, Last updated: 21/04/2023
Lamivudine Teva Pharma B.V. Blood-Borne … Lamivudine Teva Pharma B.V … for the public Lamivudine Teva Pharma B.V. lamivudine This … -
List item
Human medicine European public assessment report (EPAR): Lamivudine/Zidovudine Teva
lamivudine, zidovudine, HIV Infections
Date of authorisation: 28/02/2011,, Revision: 16, Withdrawn, Last updated: 21/03/2023
Lamivudine/Zidovudine Teva Blood-Borne Infections Communicable … Lamivudine/Zidovudine Teva … Lamivudine / Zidovudine Teva (lamivudine / zidovudine … -
List item
Human medicine European public assessment report (EPAR): Dimethyl fumarate Teva
dimethyl fumarate, Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis
Date of authorisation: 12/12/2022,, Authorised, Last updated: 21/12/2022
Dimethyl fumarate Teva Nervous System Diseases Autoimmune … Dimethyl fumarate Teva … EMEA/H/C/005963 Dimethyl fumarate Teva (dimethyl fumarate) An overview … -
List item
Human medicine European public assessment report (EPAR): Irbesartan/Hydrochlorothiazide Teva
irbesartan, hydrochlorothiazide, Hypertension
Date of authorisation: 26/11/2009,, Revision: 21, Authorised, Last updated: 31/08/2022
besartan/Hydrochlorothiazide Teva Cardiovascular Diseases Vascular … besartan/Hydrochlorothiazide Teva … besartan/Hydrochlorothiazide Teva irbesartan hydrochlorothiaz … -
List item
Human medicine European public assessment report (EPAR): Pioglitazone Teva Pharma
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 26/03/2012,, Revision: 13, Withdrawn, Last updated: 30/08/2022
Pioglitazone Teva Pharma Nutritional and Metabolic … Pioglitazone Teva Pharma … statement Pioglitazone Teva Pharma Withdrawal of the … -
List item
Human medicine European public assessment report (EPAR): Ibandronic Acid Teva
ibandronic acid, Breast Neoplasms; Neoplasm Metastasis; Fractures, Bone; Osteoporosis, Postmenopausal
Date of authorisation: 17/09/2010,, Revision: 12, Authorised, Last updated: 22/11/2022
Ibandronic Acid Teva Cancer Neoplasms Skin … EPAR) for Ibandronic Acid Teva. It explains how the The committee … of use for Ibandronic Acid Teva. What is Ibandronic Acid Teva? Ibandronic Acid Teva is a medicine that contains … -
List item
Human medicine European public assessment report (EPAR): Mycophenolate mofetil Teva
mycophenolate mofetil, Graft Rejection
Date of authorisation: 21/02/2008,, Revision: 25, Authorised, Last updated: 24/06/2022
Mycophenolate mofetil Teva Immune System Phenomena Transplantation … Mycophenolate mofetil Teva … Mycophenolate mofetil Teva 7 Westferry Circus … -
List item
Human medicine European public assessment report (EPAR): Zoledronic acid Teva
zoledronic acid, Fractures, Bone; Cancer
Date of authorisation: 16/08/2012,, Revision: 14, Authorised, Last updated: 11/10/2021
Zoledronic acid Teva Wounds and Injuries Cancer Neoplasms Fractures … Zoledronic acid Teva … public Zoledronic acid Teva zoledronic acid This is … -
List item
Human medicine European public assessment report (EPAR): Ribavirin Teva Pharma B.V.
Ribavirin, Hepatitis C, Chronic
Date of authorisation: 01/07/2009,, Revision: 14, Withdrawn, Last updated: 09/07/2021
Ribavirin Teva Pharma B.V. Hepatitis C … Ribavirin Teva Pharma B.V … seven medicines (Cilazapril Teva, Fenofibrato Pensa, Fenofibrato … -
List item
Human medicine European public assessment report (EPAR): Pramipexole Teva
pramipexole dihydrochloride monohydrate, Parkinson Disease
Date of authorisation: 18/12/2008,, Revision: 22, Authorised, Last updated: 23/11/2021
Pramipexole Teva Nervous System Diseases Central … Pramipexole Teva … Pramipexole Teva, INN-pramipexole European … -
List item
Human medicine European public assessment report (EPAR): Imatinib Teva B.V.
imatinib mesilate, Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Date of authorisation: 15/11/2017,, Withdrawn, Last updated: 09/10/2018
Imatinib Teva B.V. Dermatofibrosarcoma Gastrointestinal … Imatinib Teva B.V … Imatinib Teva B.V. imatinib imatinib … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel Teva (hydrogen sulphate)
clopidogrel (as hydrogen sulfate), Acute Coronary Syndrome; Peripheral Vascular Diseases; Myocardial Infarction; Stroke
Date of authorisation: 27/07/2009,, Revision: 18, Authorised, Last updated: 10/06/2022
Clopidogrel Teva (hydrogen sulphate) Cardiovascular … Clopidogrel Teva (hydrogen sulphate … EMEA/H/C/1053 Clopidogrel Teva clopidogrel EPAR summary … -
List item
Human medicine European public assessment report (EPAR): Zoledronic acid Teva Pharma
zoledronic acid, Osteoporosis; Osteitis Deformans; Osteoporosis, Postmenopausal
Date of authorisation: 15/08/2012,, Revision: 11, Withdrawn, Last updated: 12/12/2018
Zoledronic acid Teva Pharma Osteoporosis Osteitis … authorisation for Zoledronic acid Teva Pharma has been withdrawn … documents Zoledronic acid Teva Pharma : EPAR - Summary for … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel/Acetylsalicylic acid Teva
clopidogrel, Acetylsalicylic acid, Acute Coronary Syndrome; Myocardial Infarction
Date of authorisation: 01/09/2014, Revision: 1, Withdrawn, Last updated: 28/04/2017idogrel/Acetylsalicylic acid Teva Acute Coronary Syndrome Myocardial … idogrel/Acetylsalicylic acid Teva … idogrel/Acetylsalicylic acid Teva, INN-clopidogrel/acetylsalicylic … -
List item
Human medicine European public assessment report (EPAR): Budesonide/Formoterol Teva
Budesonide, formoterol fumarate dihydrate, Pulmonary Disease, Chronic Obstructive; Asthma
Date of authorisation: 19/11/2014, Revision: 2, Withdrawn, Last updated: 31/01/2017Budesonide/Formoterol Teva Pulmonary Disease, Chronic … Budesonide/Formoterol Teva … statement Budesonide/Formoterol Teva Withdrawal of the marketing … -
List item
Human medicine European public assessment report (EPAR): Zoledronic acid Teva Generics
zoledronic acid monohydrate, Osteoporosis; Osteitis Deformans
Date of authorisation: 27/03/2014,, Revision: 2, Withdrawn, Last updated: 08/08/2016
Zoledronic acid Teva Generics Osteoporosis Osteitis … authorisation for Zoledronic Acid Teva Generics has been withdrawn … documents Zoledronic acid Teva Generics : EPAR - Summary … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel Teva Pharma (previously Clopidogrel HCS)
clopidogrel (as hydrochloride), Myocardial Infarction; Peripheral Vascular Diseases; Stroke
Date of authorisation: 21/09/2009,, Revision: 9, Withdrawn, Last updated: 24/10/2017
Clopidogrel Teva Pharma (previously Clopidogrel … Clopidogrel Teva Pharma (previously Clopidogrel … Public statement Clopidogrel Teva Pharma Withdrawal of the … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel Teva Pharma B.V.
clopidogrel (as hydrobromide), Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke
Date of authorisation: 16/06/2011,, Revision: 4, Withdrawn, Last updated: 03/02/2015
Clopidogrel Teva Pharma B.V. Peripheral Vascular … Clopidogrel Teva Pharma B.V … Clopidogrel Teva Pharma B.V. withdrawal of … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel Teva Generics B.V.
clopidogrel (as hydrochloride), Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke
Date of authorisation: 28/10/2010,, Revision: 3, Withdrawn, Last updated: 12/05/2014
Clopidogrel Teva Generics B.V. Peripheral … Clopidogrel Teva Generics B.V … Clopidogrel Teva Generics B.V., INN-clopidogrel … -
List item
Human medicine European public assessment report (EPAR): Budesonide/Formoterol Teva Pharma B.V.
Budesonide, formoterol fumarate dihydrate, Asthma; Pulmonary Disease, Chronic Obstructive
Date of authorisation: 03/04/2020, Revision: 2, Authorised, Last updated: 08/12/2021Budesonide/Formoterol Teva Pharma B.V. Lung Diseases … Budesonide/Formoterol Teva Pharma B.V … Budesonide/Formoterol Teva Pharma B.V. 160 micrograms … -
List item
Human medicine European public assessment report (EPAR): Budesonide/Formoterol Teva Pharma B.V.
Budesonide, formoterol, Asthma
Date of authorisation: 19/11/2014, Revision: 1, Withdrawn, Last updated: 30/01/2017Budesonide/Formoterol Teva Pharma B.V. Asthma … Budesonide/Formoterol Teva Pharma B.V … statement Budesonide/Formoterol Teva Pharma B.V. Withdrawal of … -
List item
Referral: Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products
capecitabine, fluorouracil, tegafur, flucytosine, associated names: Xeloda, Teysuno, Capecitabine Accord, Capecitabine Medac, Capecitabine Teva, Ecansya (previously Capecitabine Krka), Article 31 referrals
Status: European Commission final decision, opinion/position date: 30/04/2020, EC decision date: 07/07/2020, Last updated: 23/07/2020Accord Capecitabine Medac Capecitabine Teva Ecansya (previously Capecitabine … Accord Capecitabine Medac Capecitabine Teva Ecansya (previously Capecitabine … -
List item
Direct healthcare professional communication (DHPC): 5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity
Active substance: Fluorouracil, capecitabine, tegafur, DHPC type: Referral - Article 31, Last updated: 04/06/2020Capecitabine Medac Capecitabine Teva Ecansya (previously Capecitabine … Accord Capecitabine Medac Capecitabine Teva Ecansya (previously Capecitabine … Accord Capecitabine Medac Capecitabine Teva Ecansya (previously Capecitabine …